Aethlon Medical, Inc. (AEMD)
| Market Cap | 2.07M -42.5% |
| Revenue (ttm) | n/a |
| Net Income | -7.15M |
| EPS | -10.61 |
| Shares Out | 2.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 276,056 |
| Open | 0.8900 |
| Previous Close | 0.8911 |
| Day's Range | 0.8346 - 0.9781 |
| 52-Week Range | 0.8346 - 27.4000 |
| Beta | 1.32 |
| Analysts | Hold |
| Price Target | 3.25 (+272.19%) |
| Earnings Date | Jun 10, 2026 |
About AEMD
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states. The company was founded in 1984 and is based in San Diego, California.
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for AEMD stock is "Hold." The 12-month stock price target is $3.25, which is an increase of 272.19% from the latest price.
News
Aethlon Medical announces publication demonstrating potential of Hemopurifier
Aethlon Medical (AEMD) announced publication of new peer-reviewed research in the International Journal of Molecular Sciences demonstrating that patients with Long COVID exhibit significantly increase...
Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®
Peer-reviewed study identifies altered extracellular vesicles in Long COVID and provides additional scientific rationale for evaluating the Hemopurifier® as a potential treatment SAN DIEGO, June 26, 2...
Aethlon Medical files to sell 6M shares of common stock, warrants
Maxim Group is exclusive placement agent in connection with the offering.
Aethlon Medical Registration statement: Registration filing
Aethlon Medical filed a registration statement on June 22, 2026, providing details about a securities offering with the SEC.
Aethlon Medical Slides: Corporate presentation
Aethlon Medical has posted slides in relation to its latest quarterly earnings report, which was published on June 11, 2026.
Aethlon Medical Earnings Call Transcript: Q4 2026
Advanced clinical and preclinical programs for the Hemopurifier platform, reduced operating expenses by 21.9% year-over-year, and improved net loss to $7.2 million. Clinical trials progressed with positive safety and early efficacy signals, and cash position was strengthened.
Aethlon Medical Earnings release: Q4 2026
Aethlon Medical released its Q4 2026 earnings on June 10, 2026, summarizing the period's financial results.
Aethlon Medical Annual report: Q4 2026
Aethlon Medical has published its Q4 2026 annual report on June 10, 2026.
Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update
Australian oncology study advances into Cohort 3 as enrollment continues Entered the third and final dosing cohort of the Australian oncology study, expanded the Hemopurifier intellectual property por...
Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 10, 2026
SAN DIEGO, June 2, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, tod...
Aethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness
SAN DIEGO, May 21, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, tod...
Aethlon Medical Transcript: Emerging Growth Conference 91
An Australian oncology trial is advancing to its final cohort after positive safety review, focusing on optimizing Hemopurifier treatments for patients unresponsive to leading immunotherapies. Data on immune and exosome changes are expected this quarter.
Aethlon Medical Slides: Corporate presentation
Aethlon Medical has posted slides in relation to its latest quarterly earnings report, which was published on March 27, 2026.
Advancements in Novel Immunotherapeutics in The Oncology Battle
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - March 24, 2026) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at advancements in novel immun...
Aethlon Medical advances to final cohort in AEMD-2022-06 trial
Aethlon Medical (AEMD) announced that the independent Data Safety Monitoring Board overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review of the second cohort par...
Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review
SAN DIEGO, March 24, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device fo...
Aethlon Medical Transcript: Life Sciences Virtual Investor Forum
Hemopurifier, a unique device targeting cancer-related EVs, is progressing through a safety trial in Australia with positive early data and a strong cash position. Key milestones include advancing to an efficacy trial and seeking strategic partnerships for broader development.
Aethlon Medical to evaluate range of strategic opportunities
Aethlon Medical (AEMD) announced that it is evaluating a range of strategic opportunities and has engaged Maxim Group to act as the company’s exclusive financial advisor in connection with this…
Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities
SAN DIEGO, March 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threa...
Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorC...
Aethlon Medical Transcript: Emerging Growth Virtual Conference
Hemopurifier clinical trials are advancing in Australia, focusing on solid tumor patients unresponsive to immunotherapy. Operational improvements and new patient recruitment strategies have accelerated progress, with key safety and efficacy data expected in the coming months.
Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026
Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference. SAN DIEGO, Feb. 23, 2026 /...
Aethlon Medical Earnings Call Transcript: Q3 2026
Australian oncology trial for Hemopurifier advanced with strong patient recruitment and cost controls. Operating expenses fell 27% year-over-year for the nine-month period, and compatibility work with the SLAMB system could broaden future clinical use.
Aethlon Medical Quarterly report: Q3 2026
Aethlon Medical has published its Q3 2026 quarterly earnings report on February 12, 2026.
Aethlon Medical Earnings release: Q3 2026
Aethlon Medical released its Q3 2026 earnings on February 12, 2026, summarizing the period's financial results.